Literature DB >> 23819812

Circulating miRNA-20a and miRNA-203 for screening lymph node metastasis in early stage cervical cancer.

Shan Zhao1, Desheng Yao, Junying Chen, Nan Ding.   

Abstract

BACKGROUND: MicroRNAs (miRNAs) are small, noncoding RNAs that are critical regulators of various diseases, including cancer, which may represent a novel class of cancer biomarkers. AIMS: We hypothesized that microRNA-20a (miR-20a) and microRNA-203 (miR-203), which were altered in lymphatic metastatic tissues, could be directly assayed in the serum and used to detect the lymph node status of cervical cancer patients.
METHODS: We analyzed serum levels of miR-20a and miR-203 in 80 patients with stage I-IIA of cervical cancer by quantitative real-time polymerase chain reaction assay. Blood samples were collected before surgery and therapy. Logistic regression was used to measure the influence of different variables. Receiver operating characteristic analysis could evaluate the sensitivity and specificity in separating lymph node metastasis (LNM) (+) patients from LNM (-) patients by serum miR-20a and miR-203.
RESULTS: We found that the expression level of miR-20a was significantly higher in cervical cancer patients compared to healthy controls (p=0.004), patients with LNM tended to have overexpression of miR-20a (p=0.000), the odds ratio was 1.552. The expression level of miR-203 in cervical cancer patients was also significantly increased in comparison to the healthy patients (p=0.000), while downregulated miR-203 was correlated with LNM (p=0.001), the odds ratio was 0.849. When miR-20a was used for differentiation of LNM (+) patients from LNM (-) patients, the value of the area under the receiver-operating curve (AUC) was 0.734±0.058, the sensitivity and specificity of serum miR-20a were 75% and 72.5%, respectively, the cut-off point was 3.0. But the AUC of miR-203 was only 0.658±0.061, which showed low accuracy, the sensitivity and specificity were 65% and 62.5%, respectively, the cut-off point was 0.13.
CONCLUSION: Our results suggested that the circulating miR-20a may be a potential biomarker for detecting the lymph node status of cervical cancer patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23819812     DOI: 10.1089/gtmb.2013.0085

Source DB:  PubMed          Journal:  Genet Test Mol Biomarkers        ISSN: 1945-0257


  36 in total

1.  MicroRNAs used as novel biomarkers for detecting cancer metastasis.

Authors:  Chunshan Han; Haixiang Yu; Lening Zhang; Xiaoli Li; Yonggang Feng; Hua Xin
Journal:  Tumour Biol       Date:  2014-10-31

2.  miR-152 may function as an early diagnostic and prognostic biomarker in patients with cervical intraepithelial neoplasia and patients with cervical cancer.

Authors:  Dongmei Yang; Qiumei Zhang
Journal:  Oncol Lett       Date:  2019-04-09       Impact factor: 2.967

3.  Preoperative Prediction of Lymph Node Status by Circulating Mir-18b and Mir-20a During Chemoradiotherapy in Patients with Rectal Cancer.

Authors:  Azadeh Azizian; Frank Kramer; Peter Jo; Hendrik A Wolff; Tim Beißbarth; Robert Skarupke; Markus Bernhardt; Marian Grade; B Michael Ghadimi; Jochen Gaedcke
Journal:  World J Surg       Date:  2015-09       Impact factor: 3.352

4.  Clinical significance of microRNA expressions in diagnosing uterine cancer and predicting lymph node metastasis.

Authors:  Changlong Hou; Guosheng Tan; Shiting Feng
Journal:  Tumour Biol       Date:  2014-07-31

Review 5.  Epigenetics and cervical cancer: from pathogenesis to therapy.

Authors:  Jinchuan Fang; Hai Zhang; Sufang Jin
Journal:  Tumour Biol       Date:  2014-02-20

6.  HPV 16 E7 inhibits OSCC cell proliferation, invasion, and metastasis by upregulating the expression of miR-20a.

Authors:  Jun Hu; Weili Ge; Junfeng Xu
Journal:  Tumour Biol       Date:  2016-01-19

Review 7.  Regulation of cancer metastasis by cell-free miRNAs.

Authors:  Maša Alečković; Yibin Kang
Journal:  Biochim Biophys Acta       Date:  2014-10-28

8.  The role of microRNAs in gallbladder cancer.

Authors:  Ganghua Yang; Lei Zhang; Ruixiang Li; Lin Wang
Journal:  Mol Clin Oncol       Date:  2016-05-11

Review 9.  Clinical relevance of circulating cell-free microRNAs in cancer.

Authors:  Heidi Schwarzenbach; Naohiro Nishida; George A Calin; Klaus Pantel
Journal:  Nat Rev Clin Oncol       Date:  2014-02-04       Impact factor: 66.675

10.  MicroRNA-17 family as novel biomarkers for cancer diagnosis: a meta-analysis based on 19 articles.

Authors:  Ronghe Gu; Shiqing Huang; Weiguo Huang; Yuming Li; Huijiang Liu; Lijing Yang; Zhonggui Huang
Journal:  Tumour Biol       Date:  2015-12-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.